Media reports say Merck is in discussions to acquire Revolution Medicines in a transaction valued between $28 billion and $32 billion. Sources cited by the Financial Times indicated negotiations are ongoing and no agreement has been finalized. Revolution’s late‑stage RAS program, including daraxonrasib, and its broader oncology pipeline are central to reported interest. For Merck, the move would replenish oncology assets ahead of looming patent expirations for several key products and could reshape competitive positioning in targeted small‑molecule oncology.